President Trump may think top drugmakers are ready to step up with price cuts, but Pfizer, for one, is going the other way instead.

The pharma giant hiked prices on about 40 drugs as of July 1, according to a company statement and an analyst report. It's the company's second round of increases this year. Many of the latest hikes ring in at just under 10%, a bar that several drugmakers—though not Pfizer—have publicly promised to use as a limit for their own increases.

Among the drugs with higher prices is Viagra, the iconic erectile dysfunction drug that recently went generic, according to a note from Wells Fargo analyst David Maris. Its sticker went up in January and rose again this time, for a combined hike of nearly 20%.

Whitepaper Download Reducing the Complexity and Costs of Channel Planning and Logistics How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business. Download for Free

Pfizer is far from the only company raising prices this year, of course; several drugmakers have drawn fire for their increases, including AbbVie, which continues to raise its price on Humira, already the world's biggest-selling drug. Maris highlighted dozens of price increases across Big Pharma in a January note, including a Humira hike he estimated would be worth more than $1 billion.